Saroglitazar (4mg) is manufactured by Zydus Lifesciences Ltd
Lipaglyn Tablet contains Saroglitazar, a dual action peroxisome proliferator-activated receptor (PPAR) inhibitor that aids in the management of high cholesterol, especially triglycerides, as well as blood sugar levels in people with type 2 diabetes. It acts by a unique mechanism in which it reduces the synthesis and secretion of triglycerides (a type of lipid or cholesterol in blood). It also improves insulin sensitivity of the body for better utilization of the existing insulin and hence lowers the blood sugar levels.
This is available in a 1 Strip of 10 Tablet format with an MRP of ₹501.13.
If you experience any persistent or severe side effects, consult your doctor immediately.
It is unsafe to consume alcohol with Lipaglyn Tablet.
Lipaglyn Tablet does not usually affect your ability to drive.
There is limited information available on the use of Lipaglyn Tablet in patients with kidney disease. Please consult your doctor.
There is limited information available on the use of Lipaglyn Tablet in patients with liver disease. Please consult your doctor.
Lipaglyn Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Lipaglyn Tablet should be used with caution during breastfeeding. Breastfeeding should be held until the treatment of the mother is completed and the drug is eliminated from her body.










100% Genuine
Medicines
No
Return
Online
Payment Only
Zydus Lifesciences Ltd
₹ 45.1 / Tablet
₹ 43.7 / Tablet
100% Genuine
Medicines
No
Return
Online
Payment Only
Zydus Lifesciences Ltd
₹ 45.1 / Tablet
₹ 43.7 / Tablet